TickerFacts.

Compare

Champions Oncology, Inc. vs Vir Biotechnology, Inc. vs Recursion Pharmaceuticals, Inc. vs Autolus Therapeutics plc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearChampions Oncology, Inc.
CSBR		Vir Biotechnology, Inc.
VIR		Recursion Pharmaceuticals, Inc.
RXRX		Autolus Therapeutics plc
AUTL
Year ended2026-04-302025-12-312025-12-312025-12-31
Revenue$59.42M$68.56M$74.68M$75.39M
Revenue growth (YoY)+4.4%-7.6%+26.9%+644.9%
Gross margin48.0% (computed)n/a5.0% (computed)-27.8% (computed)
Operating margin-1.9%-699.2%-867.9%-358.9%
Net margin-2.0%-638.9%-863.4%-381.4%
Net income-$1.18M-$437.99M-$644.76M-$287.53M
EPS (Diluted)-$0.08-$3.16-$1.44-$1.08
Operating cash flow-$4.47M-$391.78M-$371.81M-$283.57M
Free cash flow-$5.04M-$396.61M-$378.28M-$302.61M
Cash & equivalentsn/a$232.19M$743.29M$104.13M
Total assets$26.99M$1.00B$1.47B$589.07M
Total liabilities$22.92M$237.55M$343.26M$410.94M
Shareholders' equity$3.94M$765.28M$1.13B$178.13M
Return on year-end equity-29.8%-57.2%-57.0%-161.4%
Shares outstanding13.89M139.47M528.18Mn/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearChampions Oncology, Inc.Vir Biotechnology, Inc.Recursion Pharmaceuticals, Inc.Autolus Therapeutics plc
Latest$59.42M
Ended 2026-04-30		$68.56M
Ended 2025-12-31		$74.68M
Ended 2025-12-31		$75.39M
Ended 2025-12-31
1 year earlier$56.94M
Ended 2025-04-30		$74.20M
Ended 2024-12-31		$58.84M
Ended 2024-12-31		$10.12M
Ended 2024-12-31
2 years earlier$50.16M
Ended 2024-04-30		$86.18M
Ended 2023-12-31		$44.58M
Ended 2023-12-31		$1.70M
Ended 2023-12-31
3 years earlier$53.87M
Ended 2023-04-30		$1.62B
Ended 2022-12-31		$39.84M
Ended 2022-12-31		n/a
4 years earlier$49.11M
Ended 2022-04-30		$1.10B
Ended 2021-12-31		$10.18M
Ended 2021-12-31		n/a